UBS Group
CRBU icon

UBS Group’s Caribou Biosciences CRBU Stock Holding History

UBS Group’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$911K Buy
517,371
+258,202
+100% +$510K ﹤0.01% 5814
2026
Q1 		$492K Sell
259,169
-378,576
-59% -$650K ﹤0.01% 6098
2025
Q4 		$1.01M Buy
637,745
+318,453
+100% +$668K ﹤0.01% 5565
2025
Q3 		$744K Buy
319,292
+70,189
+28% +$133K ﹤0.01% 5802
2025
Q2 		$314K Sell
249,103
-333,775
-57% -$328K ﹤0.01% 6403
2025
Q1 		$532K Buy
582,878
+186,511
+47% +$242K ﹤0.01% 5806
2024
Q4 		$630K Buy
396,367
+239,049
+152% +$481K ﹤0.01% 5677
2024
Q3 		$308K Buy
157,318
+50,782
+48% +$104K ﹤0.01% 5550
2024
Q2 		$175K Sell
106,536
-301,739
-74% -$964K ﹤0.01% 5761
2024
Q1 		$2.1M Buy
408,275
+81,746
+25% +$504K ﹤0.01% 3905
2023
Q4 		$1.87M Buy
326,529
+175,023
+116% +$865K ﹤0.01% 3892
2023
Q3 		$724K Buy
151,506
+35,628
+31% +$221K ﹤0.01% 4369
2023
Q2 		$492K Sell
115,878
-23,877
-17% -$107K ﹤0.01% 4833
2023
Q1 		$742K Sell
139,755
-54,896
-28% -$342K ﹤0.01% 4368
2022
Q4 		$1.22M Buy
194,651
+145,749
+298% +$1.3M ﹤0.01% 3885
2022
Q3 		$515K Buy
48,902
+35,055
+253% +$327K ﹤0.01% 4309
2022
Q2 		$75K Sell
13,847
-1,794
-11% -$13.7K ﹤0.01% 5629
2022
Q1 		$143K Sell
15,641
-2,293
-13% -$24.2K ﹤0.01% 5635
2021
Q4 		$271K Buy
17,934
+8,976
+100% +$175K ﹤0.01% 5440
2021
Q3 		$214K Buy
+8,958
New +$219K ﹤0.01% 5263

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group's CRBU Position: Q2 2026 in Review

UBS Group increased its Caribou Biosciences (CRBU) stake by 100% in Q2 2026, buying an estimated $510K and bringing the position to 517,371 shares worth $911K. The position accounts for ﹤0.01% of the portfolio, ranked #5814.

UBS Group first reported a position in CRBU in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.1M in Q1 2024. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • UBS Group held 517,371 shares of Caribou Biosciences worth $911K as of Q2 2026.
  • UBS Group bought 258,202 Caribou Biosciences shares in Q2 2026, an estimated $510K.
  • Caribou Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5814 holding.
  • UBS Group first reported a position in Caribou Biosciences in Q3 2021 and has held it in 20 quarters since.
  • UBS Group's Caribou Biosciences position peaked at $2.1M in Q1 2024.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.